ClinicalTrials.gg
Not yet recruitingNCT06844799Updated Feb 25, 2025

A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis

A Phase 3 interventional study of HS-20137 and Placebo&HS-20137 in Moderate-to-severe Plaque Psoriasis, sponsored by Hansoh BioMedical R&D Company. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited — 7 open to participants now, 7 under way, 2 of them phase 3. Psoriasis · Hansoh Pharmaceutical Group Company Limited.

Planned enrollment
Largest of 10
720 · median 131
Started
2025
with 5 others
Phase 3
2 of 10
2 open now
Registered
4th of 10
by date

Among the 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited, this one has the largest planned enrollment, is one of 6 that started in 2025, is one of 2 in phase 3, and was the 4th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

7 of the 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy and safety of HS-20137 in the treatment of participants with moderate to severe plaque psoriasis.

Read the detailed description

HS-20137 is an antibody targeting IL-23, which were recommended biologic agents for the treatment of patients with moderate-to-severe psoriasis. This is a randomized, double-blinded, placebo-controlled phase 3 study, including a 4 weeks screening period, a 52 weeks double-blinded period (placebo-control period in the first 16 weeks) and a 8 weeks follow-up period (total 60 weeks). The hypothesis is that HS-20137 will be more effective in treatment of psoriasis than placebo and well tolerated. Participants with moderate-to-severe plaque psoriasis will be included in this study and received HS-20137 200mg or placebo in week 0, 4, 8 in placebo-control period and then HS-20137 200mg every 8 or 12 weeks thereafter.

03

Conditions studied

  • Moderate-to-severe Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 and above, male or female;
  2. Diagnosed plaque psoriasis for at least 6 months before randomization, with or without psoriatic arthritis;
  3. During screening and randomization, the severity of plaque psoriasis was moderate to severe, and the following conditions should be met: a) BSA≥10%; b) PASI≥12; c) sPGA≥3;
  4. Suitable for systemic therapy or phototherapy;
  5. Voluntarily participate in the research, have the ability and willingness to complete the research according to the research protocol, and sign the .

Exclusion criteria

Exclusion Criteria:

  1. Previous use of biological agents, or allergic reactions to known drug ingredients, or previous severe food or drug allergies;
  2. Confirmation of other types of psoriasis, including but not limited to guttiform psoriasis, pustular psoriasis, erythrodermic psoriasis, drug-induced exacerbation of psoriasis (including beta-blockers, non-steroidal anti-inflammatory drugs, antimalarial drugs, interferon, calcium channel blockers, or lithium induced psoriasis) from the screening period to the time before randomization;
  3. Other skin lesions, chronic inflammatory diseases or diseases, including but not limited to systemic lupus erythematosus, Sjogren's syndrome, skin sclerosis, etc., assessed by the investigator and other factors that may affect the efficacy evaluation or assessed by other researchers before randomization;
  4. Primary treatment failure occurred with previous use of similar investigatory drugs (including marketed ulinumab, gusecciumab, Tiricizumab, Lisenciumab, and IL-23 target investigatory drugs under development) (the minimum treatment standard was not reached 12 weeks after the first treatment);
  5. Use of the following drugs before randomization:

    1. Use of topical treatment drugs that affect the evaluation of psoriasis within 2 weeks before randomization;
    2. 4 weeks before randomization, Use of phototherapy, traditional systemic therapy drugs, small molecule targeted drugs that may affect the evaluation of psoriasis;
    3. use of TNF-α biologics within 3 months prior to randomization;
    4. use of other biologics for the treatment of psoriasis within 6 months before randomization; e) Use of oral or topical proprietary Chinese medicinesor other Chinese herbal medicines that affect or may affect the evaluation of psoriasis within 4 weeks prior to randomization;

    f) use of lymphocyte migration regulators or B cell and T cell regulators within 3 months before randomization, or 6 months before screening, (whichever is older) use of B-cell-specific scavenging drugs;

  6. A history of chronic recurrent infection, or opportunistic infection in the 6 months prior to screening, or hospitalization for a serious infectious disease or intravenous antibiotic use in the 2 months prior to randomization, with a confirmed or suspected illness in the 1 week prior to randomization. And Other circumstances determined by the investigator to be unsuitable for further study participation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
720 participants (estimated)

Study arms

  • Experimental
    HS-20137 arm1: HS-20137 200mg injection at week 0, 4, 8 and then every 8 weeks thereafter

    Drug: HS-20137

  • Experimental
    HS-20137 arm 2:HS-20137 200mg injection at week 0, 4, 8 and then every 12 weeks thereafter

    Drug: HS-20137

  • Experimental
    Placebo arm 1:Placebo at week 0,4,8, and HS-20137 200mg at week 16,20,24 and every8 week thereafter

    Drug: Placebo&HS-20137

  • Experimental
    Placebo arm 2:Placebo at week 0,4,8, and HS-20137 200mg at week 16,20,24 and every 12week thereafter

    Drug: Placebo&HS-20137

Interventions

  • DrugHS-20137

    HS-20137 200mg injection at week 0, 4, 8 and then every 8 or 12 weeks.

  • DrugPlacebo&HS-20137

    Placebo injection at week 0, 4, 8, and then HS-20137 200mg injection at week 16, 20, 24, and every 8 or 12 weeks thereafter

06

What researchers measure

Primary outcomes

  1. Number of Participants With Psoriasis Area and Severity Index (PASI) Score of 90 Percent or Above

    Number of participants achieving greater than or equal to 90 percent improvement in PASI at Week 16. PASI is a widely used tool for the measurement of severity of psoriasis. AND, number of participants achieving a physician global assessment (PGA) (0 \[none\] to 4 \[severe\]) of cleared or minimal at Week 16

    Time frame: At week 16

  2. Physician Global Assessment (PGA) score of 0/1

    number of participants achieving a physician global assessment (PGA) (0 \[none\] to 4 \[severe\]) of cleared or minimal at Week 16. The PGA is 5-point scale used in clinical trials of various diseases. In this the physician checks the state of the disease and gives them score from 0 (clear) to 4 (severe)

    Time frame: At week 16

Secondary outcomes

  1. PASI 90 response rate at other visit time points

    Time frame: up to 60 weeks

  2. PASI scores and changes from baseline at each visit time point

    Time frame: up to 60 weeks

  3. PASI 75 response rate and PASI 100 response rate at each visit time point

    Time frame: up to 60 weeks

  4. sPGA 0/1 response rate at other visit time points

    Time frame: during the study period except 16 weeks

  5. sPGA 0 response rate at each visit time point

    Time frame: up to 60 weeks

  6. BSA scores and changes from baseline at each visit time point

    body surface area(BSA):0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate disease, and 4 = severe disease

    Time frame: up to 60 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Mar 2027, 21 months later.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 21 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2025
First posted
Feb 25, 2025
StartEst.
Jun 10, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Jun 30, 2027
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06844799
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Jun 10, 2025 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Feb 25, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion